Publications by authors named "B M J L Mannaerts"
Article Synopsis
- Patients with inflammatory bowel disease (IBD) treated with immunomodulators or biologics face a higher risk of infections and often experience malnutrition and vitamin deficiencies.* -
- A clinical trial was conducted with 320 IBD patients to assess if a daily multivitamin and mineral supplement could lower infection rates compared to a placebo over a 24-week period.* -
- The study's results showed no significant difference in infection rates between the two groups, indicating that the supplement did not reduce the risk of infections for patients in remission while on IBD treatments.*
Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist with high antagonistic activity that blocks the GnRH receptor by competitive binding. A daily dose of 0.25 mg of ganirelix was sel5ected after a phase II study because it was the minimal, effective daily dose to prevent premature luteinizing hormone surges and this dose yielded the highest ongoing pregnancy rate per started cycle.
View Article and Find Full Text PDFPurpose: To explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol.
Methods: Clinical outcomes after one treatment cycle are reported in women with AMH: 5-35 pmol/L. Oocytes were inseminated by intracytoplasmic sperm injection, blastocyst transfer was on Day 5 and remaining blastocysts were cryopreserved.
Objective: To determine the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders (25-35 follicles with a diameter of ≥12 mm on day of triggering) who received a gonadotropin-releasing hormone (GnRH) agonist to trigger final follicular maturation.
Methods: We used individual data from women who participated in four different clinical trials and were high responders to ovarian stimulation in a GnRH antagonist protocol in this retrospective combined analysis. All women were evaluated for signs and symptoms of OHSS using identical criteria based on Golan's system (1989).